These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32606979)

  • 1. Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
    Igawa S; Ono T; Kasajima M; Manabe H; Fukui T; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Sasaki J; Naoki K
    Cancer Manag Res; 2020; 12():4911-4921. PubMed ID: 32606979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
    Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
    Igawa S; Shirasawa M; Ozawa T; Nishinarita N; Okuma Y; Ono T; Sugimoto A; Kurahayashi S; Sugita K; Sone H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Aug; 9(8):967-973. PubMed ID: 29870153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
    Imai H; Nagai Y; Minemura H; Tsuda T; Yamada Y; Wasamoto S; Kishikawa T; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Minato K; Kagamu H
    Invest New Drugs; 2022 Oct; 40(5):1066-1079. PubMed ID: 35749041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
    Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
    Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
    Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
    Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
    Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
    Sekikawa M; Murakami H; Morita M; Doshita K; Miura K; Kodama H; Morikawa N; Iida Y; Mamesaya N; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Chiba H; Takahashi T
    Thorac Cancer; 2023 Dec; 14(35):3475-3482. PubMed ID: 37873674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study.
    Nakamichi S; Kubota K; Zou F; Hayashi A; Takano N; Onda N; Matsumoto M; Miyanaga A; Noro R; Seike M
    Int J Clin Oncol; 2023 Jul; 28(7):872-879. PubMed ID: 37171692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.
    Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ichimura T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    Cancer Manag Res; 2019; 11():5757-5764. PubMed ID: 31417315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
    Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
    Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
    Uematsu S; Kitazono S; Tanaka H; Saito R; Kawashima Y; Ohyanagi F; Tozuka T; Ryosuke T; Sakatani T; Horiike A; Yoshizawa T; Saiki M; Tambo Y; Koyama J; Kanazu M; Kudo K; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
    Thorac Cancer; 2023 Jan; 14(2):168-176. PubMed ID: 36408699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride.
    Kim YH; Mio T; Masago K; Irisa K; Sakamori Y; Mishima M
    Oncol Lett; 2010 May; 1(3):569-572. PubMed ID: 22966345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.
    Kasajima M; Igawa S; Ishihara M; Otani S; Takakura A; Yokoba M; Kubota M; Sasaki J; Katagiri M; Masuda N
    Oncol Lett; 2017 Mar; 13(3):1719-1724. PubMed ID: 28454315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer.
    Shiozawa T; Sekine I; Aida Y; Watanabe H; Nakazawa K; Kurishima K; Satoh H; Hizawa N
    Case Rep Oncol; 2018; 11(3):622-632. PubMed ID: 30323752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
    Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
    Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.